Halozyme Therapeutics (HALO Quick QuoteHALO - Free Report) reported $325.72 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 40.8%. EPS of $1.54 for the same period compares to $0.91 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $286.12 million, representing a surprise of +13.84%. The company delivered an EPS surprise of +25.2%, with the consensus EPS estimate being $1.23.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product sales, net: $81.51 million versus the five-analyst average estimate of $83.34 million. The reported number represents a year-over-year change of +3.3%.
• Revenues- Royalties: $205.64 million compared to the $181.12 million average estimate based on five analysts. The reported number represents a change of +64.6% year over year.
• Revenues- Revenues under collaboration agreements: $38.57 million versus the five-analyst average estimate of $21.69 million. The reported number represents a year-over-year change of +40%.

View all Key Company Metrics for Halozyme Therapeutics here>>>

Shares of Halozyme Therapeutics have returned +10.6% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.